Nanoviricides (NNVC) Total Liabilities (2011 - 2026)
Nanoviricides (NNVC) posted Total Liabilities of $1.1 million for Q1 2026, down 8.33% sequentially from $1.2 million in Q4 2025, and down 89.04% YoY from $10.0 million in Q1 2025.
Nanoviricides (NNVC) Total Liabilities (2011 - 2026) Analysis & Trends
Nanoviricides has reported Total Liabilities for 16 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Total Liabilities fell 89.04% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 89.04% YoY) and the FY2025 annual result came in at $1.3 million, down 4.34% from the prior year.
- Total Liabilities slipped to $1.1 million in Q1 2026 per NNVC's latest filing, from $1.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $25.1 million in Q1 2022 and troughed at $412837.0 in Q2 2022.
- A 5-year average of $6.6 million and a median of $1.4 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities tumbled 98.64% in 2022, then jumped 1133.43% in 2025.
- Over 5 years, Total Liabilities stood at $20.3 million in 2022, then slumped by 95.32% to $951074.0 in 2023, then increased by 26.17% to $1.2 million in 2024, then changed by 0.0% to $1.2 million in 2025, then fell by 8.33% to $1.1 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $1.1 million, $1.2 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 10.03 Bn |
| 10 | Nanoviricides | 29.82 Mn | 26.61 Mn | - | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 10.03 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Jun 30, 2024 | 1.36 Mn |
| Mar 31, 2024 | 813,337.00 |
| Dec 31, 2023 | 951,074.00 |
| Sep 30, 2023 | 2.45 Mn |
| Jun 30, 2023 | 2.03 Mn |
| Mar 31, 2023 | 18.58 Mn |
| Dec 31, 2022 | 20.33 Mn |
| Sep 30, 2022 | 22.08 Mn |
| Jun 30, 2022 | 412,837.00 |
| Mar 31, 2022 | 25.14 Mn |
| Dec 31, 2021 | 26.81 Mn |
| Sep 30, 2021 | 29.18 Mn |
| Jun 30, 2021 | 30.26 Mn |